Skip to content
DataLookout
Menu

NECTAR IIINCT05363761

Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 2025 to May 2027 Show 5 more changesShow less
    • Eligibility criteria expanded, about 70 words
    • Enrollment closed, study ongoing
    • Study completion moved earlier from Jan 2029 to Dec 2027
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised at 3 of 3 sites
  2. Notable Lead sponsor: [Redacted] to Neurotronic, Inc.v2 Show 6 more changesShow less
    • Trial status: Withheld to Recruiting
    • Primary completion date: Jan 2025
    • Study completion date: Jan 2029
    • Start date: Apr 19, 2022
    • Study title revised
    • Collaborators expanded, about 2 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of serious device- and procedure-related complications at 30 days post procedure.
Timeframe: 30 Days
Device success
Timeframe: During the procedure

Secondary (2)

Glycemic Control:
Hypertension Control:

Arms and interventions

Ablation TreatmentExperimental

Neurotronic Infusion Catheter Treatment

Combination products: Neurotronic Infusion Catheter

Sites

3 sites in 2 countries

Panama 2, Paraguay 1